Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia

This study has been completed.
Information provided by (Responsible Party):
Sunovion Identifier:
First received: March 18, 2008
Last updated: October 29, 2013
Last verified: October 2013

Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is safe and tolerable long term among clinically stable patients. The study will also assess the long term effectiveness of lurasidone as compared to an active comparator.

Condition Intervention Phase
Schizoaffective Disorder
Drug: Lurasidone HCl
Drug: Risperidone
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Long-Term Safety, Tolerability, and Effectiveness of Lurasidone in Subjects With Schizophrenia or Schizoaffective Disorder: A Randomized, Active Comparator-Controlled Trial

Resource links provided by NLM:

Further study details as provided by Sunovion:

Primary Outcome Measures:
  • Number of Participants With Adverse Events. [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]

Enrollment: 629
Study Start Date: March 2008
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: Lurasidone HCl
40 - 120mg per day
Active Comparator: 2
Drug: Risperidone


Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Main Inclusion Criteria:

To be eligible to enter the study, each patient must comply with the following inclusion criteria:

  • Subject is 18 to 75 years on the day of signing the consent form (age parameters may be restricted further per local requirements without protocol amendment).
  • Subject meets Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria for a primary diagnosis of schizophrenia (including disorganized (295.10), paranoid (295.30), undifferentiated (295.90), catatonic (295.20), or residual (295.60) or schizoaffective disorder (295.70) subtypes.
  • Subject is not pregnant or nursing, and is not planning pregnancy within the projected duration of the study.
  • Subject will comply with the study procedures and outpatient visit requirements in the opinion of the investigator.
  • Subject voluntarily agrees to participate in the study by giving written informed consent.

Main Exclusion Criteria:

To be excluded from entering this study if they fulfil any of the criteria below:

  • Subject has a chronic organic disease of the central nervous system (other than schizophrenia).
  • Subject has current clinically significant or history of, alcohol abuse/alcoholism or drug abuse/dependence within the last 6 months.
  • In the opinion of the investigator, the subject has any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study, or interfere with the subject's participation for the full duration of the study.
  • Subject has participated in a study with an investigational compound or device within 30 days of signing informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00641745

  Show 73 Study Locations
Sponsors and Collaborators
Study Director: Medical Director, MD Sunovion
  More Information

No publications provided by Sunovion

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Sunovion Identifier: NCT00641745     History of Changes
Other Study ID Numbers: D1050237
Study First Received: March 18, 2008
Results First Received: September 1, 2011
Last Updated: October 29, 2013
Health Authority: United States: Food and Drug Administration
South Africa: Medicines Control Council
Chile: Instituto de Salud Pública de Chile
Thailand: Food and Drug Administration
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Brazil: Ministry of Health
Croatia: Ministry of Health and Social Care
Israel: Ministry of Health

Keywords provided by Sunovion:

Additional relevant MeSH terms:
Psychotic Disorders
Mental Disorders
Pathologic Processes
Schizophrenia and Disorders with Psychotic Features
Antipsychotic Agents
Central Nervous System Agents
Central Nervous System Depressants
Dopamine Agents
Dopamine Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Antagonists
Therapeutic Uses
Tranquilizing Agents processed this record on November 25, 2014